Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    Wake Forest University Health Sciences
Send
Updated on 5 August 2020
See if I qualify
cancer
measurable disease
squamous cell carcinoma of head and neck
squamous cell carcinoma
carcinoma
cetuximab
pd-1 inhibitor
head and neck cancer
metastatic squamous cell carcinoma
metastatic head and neck squamous cell carcinoma
cancer of the head
metastatic head and neck squamous cell cancer
recurrent head and neck squamous cell carcinoma

Summary

This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.

Description

Primary Objective:

To measure Overall Response Rate to treatment with Cetuximab as single agent following treatment with immunotherapy with PD-1 inhibitors alone or in combination with chemotherapy.

Secondary Objective(s):

  • Measure Duration of Response (DUR), Progression Free Survival and Overall Survival and for treatment with single agent Cetuximab after immunotherapy with PD-1 inhibitors in Head and Neck Squamous Cell Carcinoma.
  • Evaluate treatment toxicity with single agent Cetuximab in this patient population.

Exploratory Objectives:

I. Evaluate the early positron emission tomography (PET) scan ability to predict tumor response.

II. Collect quality of life (QOL) data on patient reported outcomes every six weeks and examine this data for overall tolerability of this treatment.

III. Bank saliva and blood for future studies of biomarkers. IV. Correlate treatment response with human papillomavirus (HPV) and smoking status.

OUTLINE: Patients receive cetuximab intravenously (IV) over 60-120 minutes once every week in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 week and then every 6-8 weeks thereafter.

Details
Condition Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
Age 18years - 100years
Treatment Questionnaire Administration, Cetuximab, Quality of life assessment
Clinical Study IdentifierNCT04375384
SponsorWake Forest University Health Sciences
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patients must have histologically or cytologically confirmed head and neck squamous cell carcinoma including cutaneous squamous cell cancer of the head and neck
Measurable disease by scans- at least one measurable lesion
Patients must have received previous treatment with immunotherapy with PD-1 inhibitor alone or in combination with chemotherapy in the last 6 months
Patients must have a Performance Status of 0-2
Patients must be greater than or equal to 18 years old
Willing to provide consent for collection of samples of blood and saliva as scheduled through the treatment
Subject is willing and able to comply with the protocol for the duration of the study
Willingness to donate 2 tablespoons of blood and one teaspoon of saliva before treatment, 4 times during the first 6 weeks of treatment and then every 6-8 weeks while patients is under treatment
Ability to understand and the willingness to sign an Institutional Review Board-approved informed consent document

Exclusion Criteria

Prior treatment with Cetuximab or prior therapy that specifically and directly targets the epidermal growth factor receptor (EGFR) pathway
Prior allergic reaction to Cetuximab
History of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab
Patients receiving any other investigational agents
Patient is on medications that need to be continued and that might interact with Cetuximab
Any uncontrolled condition, which in the opinion of the investigator, would interfere in the safe and timely completion of study treatment and procedures
Subject with a history of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on screening chest CT scan
Any of the following conditions: Serious or non-healing wound, ulcer, or bone fracture, history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of study enrollment, history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study enrollment, history of myocardial infarction, ventricular arrhythmia, stable/unstable angina, -symptomatic congestive heart failure, coronary/peripheral artery bypass graft or stenting or other significant cardiac disease within 6 months prior to study enrollment, history of arterial or venous thrombosis/thromboembolic event, including pulmonary embolism within 6 months of study enrollment, any condition requiring the use of immunosuppression, excluding rheumatologic conditions treated with stable doses of corticosteroids
Pregnancy, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
measurable disease
squamous cell carcinoma of head and neck
squamous cell carcinoma
carcinoma
cetuximab
pd-1 inhibitor
head and neck cancer
metastatic squamous cell carcinoma
metastatic head and neck squamous cell carcinoma
cancer of the head
metastatic head and neck squamous cell cancer
recurrent head and neck squamous cell carcinoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.